Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Galcanezumab vs Rimegepant in Episodic Migraine
NCT05127486Phase 4Completed
- Sponsor
- Eli Lilly and Company
- Start
- Dec 2021
- Primary completion
- May 2023
- Modality
- Recombinant Proteins and Enzymes, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 4 trial of galcanezumab in episodic migraine, sponsored by Eli Lilly and Company. Started Dec 2021; status: completed.
02
Drugs
galcanezumab
03
Conditions
episodic migraine
Beyond the preview
Go deeper on NCT05127486.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05127486.